97 related articles for article (PubMed ID: 11289752)
41. Long-term outcome of "prophylactic therapy" for familial medullary thyroid cancer.
Schellhaas E; König C; Frank-Raue K; Buhr HJ; Hotz HG
Surgery; 2009 Nov; 146(5):906-12. PubMed ID: 19744457
[TBL] [Abstract][Full Text] [Related]
42. RET proto-oncogene mutations in French MEN 2A and FMTC families.
Schuffenecker I; Billaud M; Calender A; Chambe B; Ginet N; Calmettes C; Modigliani E; Lenoir GM
Hum Mol Genet; 1994 Nov; 3(11):1939-43. PubMed ID: 7874109
[TBL] [Abstract][Full Text] [Related]
43. [Preventive radical surgery of C-cell carcinoma in MEN-II syndrome based on genetic screening].
Röher HD; Simon D; Goretzki PE; Höppner W; Lederbogen S; Seppel T
Chirurg; 1995 Dec; 66(12):1196-202. PubMed ID: 8582162
[TBL] [Abstract][Full Text] [Related]
44. Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype.
Frank-Raue K; Buhr H; Dralle H; Klar E; Senninger N; Weber T; Rondot S; Höppner W; Raue F
Eur J Endocrinol; 2006 Aug; 155(2):229-36. PubMed ID: 16868135
[TBL] [Abstract][Full Text] [Related]
45. Clinical characteristics and genetic screening of an extended family with MEN2A.
Algün E; Abaci N; Kösem M; Kotan C; Köseoğlu B; Boztepe H; Sekeroğlu R; Aslan H; Topal C; Ayakta H; Uygan I; Alagöl F; Erginel-Unaltuna N; Aksoy H
J Endocrinol Invest; 2002; 25(7):603-8. PubMed ID: 12150334
[TBL] [Abstract][Full Text] [Related]
46. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
Komminoth P
Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
[TBL] [Abstract][Full Text] [Related]
47. Medullary thyroid carcinoma.
Pacini F; Castagna MG; Cipri C; Schlumberger M
Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):475-85. PubMed ID: 20627492
[TBL] [Abstract][Full Text] [Related]
48. Diagnosis and treatment of medullary thyroid cancer.
Modigliani E; Franc B; Niccoli-sire P
Baillieres Best Pract Res Clin Endocrinol Metab; 2000 Dec; 14(4):631-49. PubMed ID: 11289739
[TBL] [Abstract][Full Text] [Related]
49. Novel germline RET proto-oncogene mutations associated with medullary thyroid carcinoma (MTC): mutation analysis in Japanese patients with MTC.
Kitamura Y; Goodfellow PJ; Shimizu K; Nagahama M; Ito K; Kitagawa W; Akasu H; Takami H; Tanaka S; Wells SA
Oncogene; 1997 Jun; 14(25):3103-6. PubMed ID: 9223675
[TBL] [Abstract][Full Text] [Related]
50. Prophylactic thyroidectomies in MEN2 syndrome: Management and outcomes.
Bussières V; Roy S; Deladoey J; Rousseau É; St-Vil D; Piché N
J Pediatr Surg; 2018 Feb; 53(2):283-285. PubMed ID: 29336779
[TBL] [Abstract][Full Text] [Related]
51. [Germline mutations of the ret proto-oncogene in Chilean patients with hereditary and sporadic medullary thyroid carcinoma].
Wohllk N; Becker P; Youlton R; Cote GJ; Gagel RF
Rev Med Chil; 2001 Jul; 129(7):713-8. PubMed ID: 11552438
[TBL] [Abstract][Full Text] [Related]
52. [Management of multiple endocrine neoplasia syndrome type 2 families in association with rare germline mutations of the RET proto-oncogene].
Fitze G; Saeger HD; Roesner D; Schackert HK
Klin Padiatr; 2004; 216(5):270-6. PubMed ID: 15455293
[TBL] [Abstract][Full Text] [Related]
53. A novel point mutation in the intracellular domain of the ret protooncogene in a family with medullary thyroid carcinoma.
Hofstra RM; Fattoruso O; Quadro L; Wu Y; Libroia A; Verga U; Colantuoni V; Buys CH
J Clin Endocrinol Metab; 1997 Dec; 82(12):4176-8. PubMed ID: 9398735
[TBL] [Abstract][Full Text] [Related]
54. A novel somatic mutation in the RET proto-oncogene in familial medullary thyroid carcinoma with a germline codon 768 mutation.
Miyauchi A; Egawa S; Futami H; Kuma K; Obara T; Yamaguchi K
Jpn J Cancer Res; 1997 Jun; 88(6):527-31. PubMed ID: 9263528
[TBL] [Abstract][Full Text] [Related]
55. Management of patients with hereditary medullary thyroid carcinoma.
Fitze G
Eur J Pediatr Surg; 2004 Dec; 14(6):375-83. PubMed ID: 15630638
[TBL] [Abstract][Full Text] [Related]
56. [Clinical diagnosis and treatment of familial medullary thyroid carcinoma caused by a p.C618Y RET proto-oncogene mutation in a Chinese pedigree].
Zhao JQ; Guo L; Qi XP; Chen ZG; Wang KJ; Lou JL; Yu XH; Cheng J; Jin HY; Li XL; Ying RB; Zhang XN
Zhonghua Yi Xue Za Zhi; 2013 Feb; 93(6):440-4. PubMed ID: 23660264
[TBL] [Abstract][Full Text] [Related]
57. Single center experience in primary surgery for medullary thyroid carcinoma.
Ukkat J; Gimm O; Brauckhoff M; Bilkenroth U; Dralle H
World J Surg; 2004 Dec; 28(12):1271-4. PubMed ID: 15517488
[TBL] [Abstract][Full Text] [Related]
58. When is prophylactic thyroidectomy indicated for patients with the RET codon 609 mutation?
Calva D; O'Dorisio TM; Sue O'Dorisio M; Lal G; Sugg S; Weigel RJ; Howe JR
Ann Surg Oncol; 2009 Aug; 16(8):2237-44. PubMed ID: 19472011
[TBL] [Abstract][Full Text] [Related]
59. Recommendations for reporting C cell pathology of the thyroid.
Kaserer K; Scheuba C; Neuhold N; Weinhäusel A; Vierhapper H; Niederle B
Wien Klin Wochenschr; 2002 Apr; 114(7):274-8. PubMed ID: 12089863
[TBL] [Abstract][Full Text] [Related]
60. [Consequences of clinical genetic analysis of RET proto-oncogene].
Włoch J; Wygoda Z; Wiench M; Gubała E; Kula D; Oczko M; Lange D; Jarzab B
Wiad Lek; 2001; 54 Suppl 1():406-14. PubMed ID: 12182057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
